3SBio (HKG:1530) said its 707 injection was granted a breakthrough therapy designation by China's National Medical Products Administration, according to a late Thursday bourse filing.
This designation provides benefits for 707's development as a first-line treatment for PD-L1-positive locally advanced or metastatic non-small cell lung cancer, the filing stated.
Drugs with that designation are entitled to policy support, prioritized communication resources, enhanced guidance, and accelerated development.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。